Profit attributable to shareholders surged 28% to S$995.3 million in FY-24, with strong sales growth and higher dividends. NBEV declined due to actuarial changes, while medical insurance costs remain a key focus.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.